* Sequus Pharmaceuticals Inc., of Menlo Park, Calif., said Amphocil,which is a combination of the anti-fungal amphotericin B and thecompany's lipid-based drug delivery system, was cleared formarketing in Sweden as a second-line treatment for systemicmycoses. Amphocil is approved in 10 countries outside the U.S. andis under review by the FDA.

* U.S. Bioscience Inc., of West Conshohocken, Pa., saidstockholders approved a one-for-two reverse split of the company'sstock.

(c) 1997 American Health Consultants. All rights reserved.